Cambridge Trust’s Avanos Medical AVNS Stock Holding History

Cambridge Trust’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4	Closed	-$90	–	660
2023 Q4	$90	Buy	+4	New	+$83	﹤0.01%	685

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Cambridge Trust's AVNS Position: Q1 2024 in Review

Cambridge Trust sold out of Avanos Medical (AVNS) in Q1 2024, closing a stake of 4 shares — an estimated $90 sold.

Cambridge Trust first reported a position in AVNS in Q4 2023 and held it in 1 quarter. The position peaked at $90 in Q4 2023. 261 funds tracked by Wall St. Rank hold AVNS as of Q1 2024.

Cambridge Trust reported no remaining Avanos Medical position as of Q1 2024 after selling out during the quarter.
Cambridge Trust sold 4 Avanos Medical shares in Q1 2024, an estimated $90.
Cambridge Trust first reported a position in Avanos Medical in Q4 2023 and held it in 1 quarter.
Cambridge Trust's Avanos Medical position peaked at $90 in Q4 2023.
261 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.